KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Accumulated Expenses: 2018-2024

Historic Other Accumulated Expenses for Amneal Pharmaceuticals (AMRX) over the last 6 years, with Dec 2024 value amounting to $31.8 million.

  • Amneal Pharmaceuticals' Other Accumulated Expenses rose 34.52% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 34.52%. This contributed to the annual value of $31.8 million for FY2024, which is 58.75% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $31.8 million for FY2024, which was down 58.75% from $77.0 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Other Accumulated Expenses registered a high of $107.5 million during FY2022, and its lowest value of $31.8 million during FY2024.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $77.0 million (2023), whereas its average is $72.1 million.
  • In the last 5 years, Amneal Pharmaceuticals' Other Accumulated Expenses skyrocketed by 85.32% in 2022 and then slumped by 58.75% in 2024.
  • Over the past 4 years, Amneal Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $58.0 million in 2021, then soared by 85.32% to $107.5 million in 2022, then dropped by 28.37% to $77.0 million in 2023, then crashed by 58.75% to $31.8 million in 2024.